View More Recent Stories

Jul 12, 2016 04:19PM Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016
Jun 6, 2016 07:35AM Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO A
Jun 6, 2016 07:30AM Exelixis (EXEL), Ipsen Announce Positive METEOR Trial Subgroup Analyses in RCC
Jun 6, 2016 07:30AM Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO A
Jun 5, 2016 07:53AM Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Re
Jun 5, 2016 07:35AM Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced re
Jun 5, 2016 07:30AM Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting
May 23, 2016 09:05AM Exelixis (EXEL) Announces Cabozantinib Phase 2 Met Primary Endpoint in RCC
May 23, 2016 09:02AM Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell
May 5, 2016 04:05PM Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10
May 4, 2016 04:05PM Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update
Apr 26, 2016 04:05PM Exelixis to Release First Quarter 2016 Financial Results on Wednesday, May 4, 2016
Apr 25, 2016 01:54PM Exelixis (EXEL) Announces FDA Approval for CABOMETYX to Treat Advanced RCC
Apr 25, 2016 01:52PM ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Apr 25, 2016 01:52PM Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Jan 6, 2014 09:37AM Pre-Open Stock Movers 1/6: (SCTY) (RDWR) (SIRI) Higher; (SCSS) (HGG) (TWTR) Lower (more...)
View More Recent Stories